The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
LEDAGA (Recordati Rare Diseases Australia Pty Ltd)
Product name
LEDAGA
Date registered
Evaluation commenced
Decision date
Approval time
170 (255 working days)
Active ingredients
chlormethine hydrochloride
Registration type
NCE/NBE
Indication
LEDAGA (gel) is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.